MA

Mainz BioMed N.V.

Develops at-home diagnostic tests for the early detection of life-threatening cancers.

F

Overview

Corporate Details

ISIN(s):
NL0015000LC2 (+3 more)
LEI:
894500XWJE7LIJNYQ547
Country:
Germany
Address:
Robert-Koch-Strasse 50, 55129 Mainz
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mainz BioMed N.V. is a molecular genetics company that develops and commercializes market-ready in-vitro diagnostic (IVD) solutions for the early detection of life-threatening conditions. The company's flagship product, ColoAlert®, is a non-invasive, at-home screening test for colorectal cancer (CRC) marketed in Europe. Mainz BioMed is also advancing its product pipeline with proprietary genetic testing methods for other deadly conditions, including pancreatic cancer, to provide accessible and reliable early detection solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 15:01
Regulatory News Service
Mainz Biomed to Attend 2025 Maxim Growth Summit
English 10.2 KB
2025-10-08 15:00
Regulatory News Service
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel …
English 12.2 KB
2025-09-30 14:01
Regulatory News Service
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Sc…
English 12.1 KB
2025-09-23 14:01
Regulatory News Service
Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland
English 11.5 KB
2025-09-02 14:01
Regulatory News Service
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
English 11.2 KB
2025-08-13 14:01
Regulatory News Service
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert
English 11.6 KB
2025-07-23 14:01
Business and Financial Review
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for…
English 11.2 KB
2025-07-15 14:01
Earnings Release
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colore…
English 15.5 KB
2025-06-25 14:01
Regulatory News Service
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Scr…
English 11.1 KB

Automate Your Workflow. Get a real-time feed of all Mainz BioMed N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mainz BioMed N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mainz BioMed N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom PSY
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland PUR
Puretech Health PLC Logo
A clinical-stage biotherapeutics company developing new medicines for devastating diseases.
United States of America PRTC
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland CRM
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France ALQGC
Quratis Inc. Logo
Develops infectious disease vaccines and offers biologics CDMO services for global health.
South Korea 348080
Recordati Industria Chimica e Farmaceutica Logo
Global pharma group developing drugs for common/rare diseases & supplying APIs worldwide.
Italy REC
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel REKA
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden RESP

Talk to a Data Expert

Have a question? We'll get back to you promptly.